Literature DB >> 3619447

Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists.

L Clarke, D J Waxman.   

Abstract

Folylpolyglutamate synthetase (FPGS) was isolated from human liver cytosol by 0-30% (w/v) ammonium sulfate fractionation and characterized biochemically. Using aminopterin (AMT), L-[3H]glutamate and MgATP as cosubstrates, maximal gamma-L-glutamylation activity was observed in the presence of the activators KCl and NaHCO3. ATP and 2-mercaptoethanol were each required for enzyme activity and stability. In the absence of ATP, human liver FPGS rapidly inactivated at 37 degrees C (t1/2 approximately 8 min), whereas FPGS isolated from rabbit liver was significantly more stable (t1/2 = 68 min). Both folates and antifolates were effectively polyglutamylated by the isolated human liver enzyme. Km parameters determined for AMT (Km = 4.3 microM) were similar to those determined for several reduced folates (tetrahydrofolic acid, dihydrofolic acid, and folinic acid; Km = 3-7 microM), while significantly higher Km values were observed for methotrexate (MTX) and 5-methyltetrahydrofolic acid (Km = 50-60 microM) and for folic acid (Km = 100 microM). All of the substrates examined exhibited Vmax values ranging from 30 to 90% of the AMT value (Vmax = 935 pmol product/mg/h). The order of reactivity for these substrates differed from that determined in parallel studies for FPGS isolated from rat and rabbit liver. In the case of AMT and several reduced folates, inhibition of human liver FPGS was observed at substrate concentrations at or above 50-250 microM. FPGS isolated from six individual human livers exhibited highly similar biochemical and kinetic properties, suggesting the presence of the same or at least highly similar enzyme species in each individual, with a five-fold interindividual range in specific activities observed. Comparison of MTX with its higher polyglutamates (MTX-Glu2 to MTX-Glu6) as FPGS substrates indicated a significant decrease in Vmax values with increasing glutamate chain length which was partially compensated for by a corresponding decrease in Km. Consistent with these observations, the isolated enzyme was unable to synthesize polyglutamates higher than MTX-Glu3 when MTX was supplied as substrate, raising the question as to how MTX polyglutamates containing up to five or six gamma-L-glutamate residues are formed in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619447     DOI: 10.1016/0003-9861(87)90616-3

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate.

Authors:  Ryan S Funk; Leon van Haandel; J Steven Leeder; Mara L Becker
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

2.  Methotrexate Resistance in Datura innoxia (Uptake and Metabolism of Methotrexate in Wild-Type and Resistant Cell Lines).

Authors:  K. Wu; I. J. Atkinson; E. A. Cossins; J. King
Journal:  Plant Physiol       Date:  1993-02       Impact factor: 8.340

3.  Characterisation of the bifunctional dihydrofolate synthase-folylpolyglutamate synthase from Plasmodium falciparum; a potential novel target for antimalarial antifolate inhibition.

Authors:  Ping Wang; Qi Wang; Yonghong Yang; James K Coward; Alexis Nzila; Paul F G Sims; John E Hyde
Journal:  Mol Biochem Parasitol       Date:  2010-03-27       Impact factor: 1.759

4.  Effect of folic acid on methotrexate induction of sulfotransferases in rats.

Authors:  Sangita Maiti Dutta; Smarajit Maiti; Guangping Chen
Journal:  Drug Metab Lett       Date:  2008-04

5.  Expression cloning of a human cDNA encoding folylpoly(gamma-glutamate) synthetase and determination of its primary structure.

Authors:  T A Garrow; A Admon; B Shane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

6.  Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.

Authors:  Roxana Daneshjou; Eric R Gamazon; Ben Burkley; Larisa H Cavallari; Julie A Johnson; Teri E Klein; Nita Limdi; Sara Hillenmeyer; Bethany Percha; Konrad J Karczewski; Taimour Langaee; Shitalben R Patel; Carlos D Bustamante; Russ B Altman; Minoli A Perera
Journal:  Blood       Date:  2014-07-30       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.